Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors

Harrington, Kevin; Kitano, Shigehisa; Parkes, Eileen; Moreno, Irene; Alonso-Casal, Guzman; Gambardella, Valentina

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Harrington, Kevin
dc.contributor.author	Kitano, Shigehisa
dc.contributor.author	Parkes, Eileen
dc.contributor.author	Moreno, Irene
dc.contributor.author	Alonso-Casal, Guzman
dc.contributor.author	Gambardella, Valentina
dc.date.accessioned	2025-03-21T09:31:00Z
dc.date.available	2025-03-21T09:31:00Z
dc.date.issued	2025-01-16
dc.identifier.citation	Harrington K, Kitano S, Gambardella V, Parkes EE, Moreno I, Alonso G, et al. Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors. Futur Oncol. 2025 Jan 16;21(2):195-200.
dc.identifier.issn	1744-8301
dc.identifier.uri	http://hdl.handle.net/11351/12812
dc.description	Anticòs PD-1; Càncer; Immunoteràpia
dc.description.sponsorship	This article was funded by Boehringer Ingelheim International GmbH.
dc.language.iso	eng
dc.publisher	Taylor & Francis
dc.relation.ispartofseries	Future Oncology;21(2)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Quimioteràpia combinada
dc.subject	Càncer - Immunoteràpia
dc.subject	Posologia
dc.subject.mesh	Antineoplastic Combined Chemotherapy Protocols
dc.subject.mesh	Neoplasms
dc.subject.mesh	/drug therapy
dc.subject.mesh	Maximum Tolerated Dose
dc.title	Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1080/14796694.2024.2441107
dc.subject.decs	protocolos de quimioterapia antineoplásica combinada
dc.subject.decs	neoplasias
dc.subject.decs	/farmacoterapia
dc.subject.decs	dosis máxima tolerada
dc.relation.publishversion	https://doi.org/10.1080/14796694.2024.2441107
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Harrington K] The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, London, UK. [Kitano S] Japanese Foundation for Cancer Research, Tokyo, Japan. [Gambardella V] INCLIVA Biomedical Research Institute, Hospital Clínico de Valencia, Valencia, Spain. [Parkes EE] Department of Oncology, University of Oxford, Churchill Hospital, Oxford, UK. [Moreno I] START Madrid, CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain. [Alonso G] Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid	39817655
dc.identifier.wos	001398428300001
dc.rights.accessrights	info:eu-repo/semantics/openAccess